Citation Impact
Citing Papers
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes
2014
Acromegaly
2006 Standout
The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis
2018 Standout
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma
2005
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future
2016
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
2009
<p>The journey from gene knockout to clinical medicine: telotristat and sotagliflozin</p>
2019
Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
2016
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Radioembolization with Yttrium-90 Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors
2016
Classification and functions of enteroendocrine cells of the lower gastrointestinal tract
2011
Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors
2006
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
2003
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
2006
Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways
2017 StandoutNobel
Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral Center
2004
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors
2003
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
2004
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines
2009
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids
2010
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
2014
Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
2009 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
2008
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
2004
Combination therapy in combating cancer
2017 Standout
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
2011
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
2009
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
2017 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Dialkylcarbamoyl chloride (DACC)-coated dressings in the management and prevention of wound infection: a systematic review
2017 StandoutNobel
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
2004
Works of M. Wied being referenced
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Octreotide Versus Octreotide Plus Interferon-Alpha in Endocrine Gastroenteropancreatic Tumors: A Randomized Trial
2005
Combination Therapy With Octreotide and α-Interferon:
1999
Treatment of Neuroendocrine GEP Tumours with Somatostatin Analogues
2000
Transarterial Chemoembolization of Advanced Liver Metastases of Neuroendocrine Tumors – A Retrospective Single-Center Analysis
2003
Prognostic factors in patients with neuroendocrine gastroenteropancreatic (GEP) tumors
2000
Parameters of prognosis in patients with non-functioning neuroendocrine tumors
2001
Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group
2009